A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 501–600 of 1,000
IgM MGUS associated with anti-MAG neuropathy: a single institution experience
Talamo, G., Mir, M. A., Pandey, M. K., Sivik, J. M., & Raheja, D. (2015) · Annals of Hematology · doi:10.1007/s00277-014-2294-7 · Cited by 24
Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma
Steiner, N., Göbel, G., Michaeler, D., Platz, A.-L., Prokop, W., Wolf, A. M., Wolf, D., Duftner, C., & Gunsilius, E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003193 · Cited by 24
McShane, C. M., Murray, L., Engels, E. A., Landgren, O., & Anderson, L. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28479 · Cited by 26
“MM is consistently preceded by a premalignant disease, monoclonal gammopathy of undetermined significance (MGUS),(6,7) which carries on average a 1% annual risk of progression to MM or other lymphoproliferative disorders.(8) Both MGUS and MM are associated with B-cell dysfunction and impaired cellular and humoral immu…”
BackgroundZojer, N., Ludwig, H., Fiegl, M., Stevenson, F. K., & Sahota, S. S. (2003) · Blood · doi:10.1182/blood-2002-09-2825 · Cited by 24
Greenberg, A. J., Lee, A. M., Serie, D., McDonnell, S. K., Cerhan, J. R., Liebow, M., Larson, D. R., Colby, C. L., Norman, A. D., Kyle, R. A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.232 · Cited by 29
Self-citationTsai, D. E., Aqui, N. A., Tomaszewski, J. E., Olthoff, K. M., Ahya, V. N., Kotloff, R. M., Bloom, R. D., Brozena, S. C., Hodinka, R. L., Stadtmauer, E. A., et al. (2005) · Clinical Transplantation · doi:10.1111/j.1399-0012.2005.00388.x · Cited by 24
Sánchez, M. L., Almeida, J., López, A., Sayagués, J. M., Rasillo, A., Sarasquete, E. A., Balanzategui, A., Tabernero, M. D., Diaz‐Mediavilla, J., Barrachina, C., et al. (2006) · PubMed · Cited by 24
Occurrence of Double Monoclonal Bands on Protein Electrophoresis: An Unusual Finding
Srinivasan, V. K., Bhagat, P., Bansal, F., & Chhabra, S. (2015) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-015-0622-2 · Cited by 23
Circulating extracellular vesicle‐associated CD163 and CD206 in multiple myeloma
Kvorning, S. L., Nielsen, M. C., Andersen, N. F., Hokland, M., Andersen, M. N., & Møller, H. J. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13371 · Cited by 26
Choa, R., Panaroni, C., Bhatia, R., & Raje, N. S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010822 · Cited by 25
“Non-IgM MGUS poses a higher risk of transformation to MM,(15) and the overall rate of progression from MGUS to MM is ~1% per year, regardless of the duration of follow-up.(16) The prevalence of MGUS is higher in men and African Americans, which may be partially attributable to the higher rates of MM observed in this p…”
BackgroundKloth, J. K., Hillengaß, J., Listl, K., Kilk, K., Hielscher, T., Landgren, O., Delorme, S., Goldschmidt, H., Kauczor, H., & Weber, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28877 · Cited by 23
Wu, D., Guo, X., Su, J., Chen, R., Berenzon, D. P., Guthold, M., Bonin, K., Zhao, W., & Zhou, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.11.019 · Cited by 25
Diagnosis and management of neuropathies associated with plasma cell dyscrasias
E, E. R. P., Marks, D. K., & Raza, S. (2017) · Hematological Oncology · doi:10.1002/hon.2417 · Cited by 23
“5 g/dL, an elevated free light chain ratio or a non‐IgG subclass.(72,73) The prevalence of MGUS is 5% in those greater than 70 years of age and greater than 7% in those over 85 years of age.”
BackgroundMature lymphoid malignancies: origin, stem cells, and chronicity
Husby, S., & Grønbæk, K. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017008854 · Cited by 25
Vallet, S., Hoyle, N. R., Kyle, R. A., Podar, K., & Pecherstorfer, M. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1421757 · Cited by 23
“of approximately one percent per year, the majority of patients with MGUS will never progress to MM [2].”
BackgroundSelf-citationSimeone, F. J., Harvey, J. P., Yee, A. J., O’Donnell, E., Raje, N. S., Torriani, M., & Bredella, M. A. (2018) · Skeletal Radiology · doi:10.1007/s00256-018-3066-6 · Cited by 23
Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma
van Beers, E. H., Huigh, D., Bosman, L., de Best, L., Kuiper, R., Spaan, M., van Duin, M., Sonneveld, P., Dumee, B., & van Vliet, M. H. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.10.010 · Cited by 23
Ouedraogo, D. E., Makinson, A., Vendrell, J.-P., Casanova, M.-L., Nagot, N., Cezar, R., Bolloré, K., Taaba, Y. A., Foulongne, V., Badiou, S., et al. (2013) · Blood · doi:10.1182/blood-2012-12-470393 · Cited by 23
Neriishi, K., Nakashima, E., & Suzuki, G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04287.x · Cited by 23
“The prevalence of MGUS is reportedly 2Æ0% in those over 50 years old and 3Æ0% in those over 70 years old (Kyle et al, 2002).”
BackgroundResultInfluentialImmunoglobulin D amyloidosis: a distinct entity
Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Dispenzieri, A. A., Greipp, P. R., Kumar, S. K., Lacy, M. Q., Lust, J. A., Leung, N., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358895 · Cited by 23
“Autonomic failure, n (%) 3 (6) 10 (7) .”
Self-citationMartin-Ayuso, M., Almeida, J., Pérez‐Andrés, M., Cuello, R., Galende, J., González-Fraile, M. I., Martín–Núñez, G., Ortega, F., Rodríguez, M. J., Miguel, J. F. S., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0127 · Cited by 24
“Monoclonal gammopathies (MGs) are a heterogeneous group of diseases characterized by the expansion of clonal plasma cells (PCs) [1, 2 ]. Malignant MGs, for example, multiple myeloma (MM) and plasma cell leukemia (PCL), may develop from a previous MG of undetermined significance (MGUS)—the most common PC disorder— or e…”
BackgroundMethodDyck, P. J., Taylor, B. V., Davies, J. L., Mauermann, M. L., Litchy, W. J., Klein, C. J., & Dyck, P. J. B. (2015) · Muscle & Nerve · doi:10.1002/mus.24707 · Cited by 23
“, lymphoma or primary amyloidosis).(34) Patients with asymmetric multifocal CIDP (Lewis–Sumner syndrome) were excluded.”
BackgroundPrimary bone marrow B-cell lymphoma: report of four cases.
Strauchen, J. A. (2003) · PubMed · Cited by 23
Monoclonal gammopathies and malignancies in patients with chronic urticaria
Karakelides, M., Monson, K. L., Volcheck, G. W., & Weiler, C. R. (2006) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2006.02982.x · Cited by 23
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22
Luca, L. D., Laurenzana, I., Trino, S., Lamorte, D., Caivano, A., & Musto, P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1583103 · Cited by 22
“As a consequence, we postulate that, in these disorders, EVs could be useful ‘predictors’ of early progression in symptomatic myeloma in patients with MGUS and SM, as well as of quality of response, resistance or early relapse in MM patients.”
BackgroundInfluentialAberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert, C., Hemelrijck, L. A. V., Maes, A., Veirman, K. D., Menu, E., Vanderkerken, K., & Bruyne, E. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.979569 · Cited by 24
Assumption-Lean Cox Regression
Vansteelandt, S., Dukes, O., Lancker, K. V., & Martinussen, T. (2022) · Journal of the American Statistical Association · doi:10.1080/01621459.2022.2126362 · Cited by 22
“…methods, we consider the analysis of an observational study on the predictive relationship between the initial concentration of serum monoclonal protein and death in 1338 patients with monoclonal gammopathy of undetermined significance (MGUS), residing in southeastern Minnesota (Kyle et al. 2002).”
MethodÓskarsson, J. Þ., Rögnvaldsson, S., Þorsteinsdóttir, S., Aspelund, T., Gunnarsson, S. B., Hákonardóttir, G. K., Sigurðardóttir, G. Á., Þórðardóttir, Á. R., Gíslason, G. K., Ólafsson, A., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00951-2 · Cited by 23
Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 26
Kumar, S. K., Dingli, D., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07069.x · Cited by 22
“…myeloma (MM) represents a late stage in the spectrum of plasma cell proliferative disorders and can be preceded by a diagnosis of monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma (PC) or smoldering MM (SMM) (Kyle et al, 2002, 2003, 2007; Kyle & Rajkumar, 2004).”
BackgroundSelf-citationAcquired cutis laxa following urticarial vasculitis associated with IgA myeloma
Turner, R. B., Haynes, H. A., Granter, S. R., & Miller, D. M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.09.059 · Cited by 22
Role of Positron Emission Tomography/Computed Tomography in Bone Malignancies
Peller, P. J. (2013) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2013.05.005 · Cited by 22
“The progression from MGUS to MM is slow but long term, approximately 1% per year for the next 15 years.(88,89) There are 3 staging systems for myeloma: the International Staging System (ISS), the Durie-Salmon staging system, and the Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART).”
BackgroundNeuropathy Associated with the Monoclonal Gammopathies
Kyle, R. A., & Dyck, P. J. B. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-9491-7.50103-4 · Cited by 22
Self-citationSkalická, P., Ďuďáková, Ľ., Palos, M., Huna, L. J., Evans, C. J., Mahelková, G., Meliska, M., Stopka, T., Tuft, S. J., & Lišková, P. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14123 · Cited by 22
“condition, the cumulative probability of progression to malignancy is estimated to be 12% at 10 years, increasing to 30% at 25 years (Kyle et al. 2002).”
BackgroundRisk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 26
Prevalence, clinical aspects, and natural history of IgM MGUS
McMaster, M. L., & Landgren, O. (2010) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20550 · Cited by 29
“Several prognostic markers indicating risk for progression to myeloma have been proposed, including M-protein isotype (14), M-protein size (14), serum free light chain ratio (21), Bence Jones proteinuria (22), reduction of uninvolved polyclonal immunoglobulins (22), and proportion and atypia of bone marrow plasma cell…”
BackgroundRajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.23204 · Cited by 24
“Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder prevalent in over 4% of the general population over the age of 50, and carries a risk of progression of approximately 1% per year [4,5].”
BackgroundSelf-citationDevelopment of MGUS in psoriatic patients: a possible undiagnosed event during anti‐TNF‐α‐treatment
Prignano, F., Pescitelli, L., Ricceri, F., Ermini, A., & Lotti, T. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04216.x · Cited by 22
MYC inhibitors in multiple myeloma
Martínez-Martín, S., & Soucek, L. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.55 · Cited by 27
Parisi, M., Dogliotti, I., Clerico, M., Bertuzzo, D., Benevolo, G., Orsucci, L., Schiavetti, I., Cavallo, R., Cavallo, F., Ragaini, S., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15553 · Cited by 21
Pojero, F., Casuccio, A., Parrino, M. F., Cardinale, G., Romano, G. C., Caruso, C., & Gervasi, F. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21218 · Cited by 21
New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies
Kapoulas, S., Raptis, V., & Papaioannou, M. (2015) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2014.12.005 · Cited by 23
Autoimmune-mediated peripheral neuropathies and autoimmune pain
Klein, C. J. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63432-0.00023-2 · Cited by 21
Direct evidence for a polygenic etiology in familial multiple myeloma
Halvarsson, B.-M., Wihlborg, A.-K., Ali, M., Lemonakis, K., Johnsson, E., Niroula, A., Cibulskis, C., Weinhold, N., Försti, A., Alici, E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003111 · Cited by 21
Olechnowicz, S. W. Z., Weivoda, M. M., Lwin, S. T., Leung, S. K., Gooding, S., Nador, G., Javaid, M. K., Ramasamy, K., Rao, S. R., Edwards, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50591-5 · Cited by 21
Bumma, N., Nagasaka, M., Hemingway, G., Miyashita, H., Chowdhury, T., Kim, S., Vankayala, H. M., Ahmed, S., & Jasti, P. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.11.014 · Cited by 24
Hillengaß, J., Zechmann, C. M., Nadler, A., Hose, D., Cremer, F. W., Jauch, A. S., Heiß, C., Benner, A., Ho, A. D., Bartram, C. R., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23455 · Cited by 23
“Although we did not integrate data on clinical course of disease into this analysis as we focused on the genetic mechanisms underlying increased angiogenesis, we took into considerations that the clinical course of MGUS and asymptomatic myeloma can be very different with some patients having longterm stable disease wh…”
MethodThakkinstian, A., Tran, H. A., Reeves, G. E. M., Murch, S., & Attia, J. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0712-z · Cited by 21
Different biological behaviour of Waldenström macroglobulinemia in two dogs
Gentilini, F., Calzolari, C., Buonacucina, A., Tommaso, M. D., Militerno, G., & Bergamini, P. F. (2005) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5810.2005.00068.x · Cited by 21
“The minimum thresholds for distinguishing WM from MGUS were established in 30 g L 1 and 20% of bone marrow infiltration.(24) Nevertheless, Mansoor et al.”
BackgroundTransient paraproteinemia: an intriguing immunological anomaly.
Strobel, S. L. (2003) · PubMed · Cited by 21
Rawstron, A. C., Hillmen, P., & Houlston, R. S. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.05.001 · Cited by 21
Papadaki, H. Α., Pontikoglou, C. G., Stavroulaki, E., Minadakis, G., Eliopoulos, D. A., Pyrovolaki, K., Skordilis, P., & Eliopoulos, G. D. (2005) · Annals of Hematology · doi:10.1007/s00277-004-0996-y · Cited by 21
“The condition is more frequent in older age groups and may be transformed to multiple myeloma or to a related malignancy at a rate of 1% per year [3, 4].”
BackgroundNicol, J. L., Chong, J. E., McQuilten, Z., Mollee, P. N., Hill, M. M. C., & Skinner, T. L. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.10.003 · Cited by 21
Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders
Argentou, N., Vassilopoulos, G., Ιωάννου, Μ., Germenis, A. E., & Speletas, M. G. (2013) · Leukemia · doi:10.1038/leu.2013.294 · Cited by 20
Multiple myeloma: a clinical overview.
Anderson, K. C. (2011) · PubMed · Cited by 27
The Process of Amyloid Formation due to Monoclonal Immunoglobulins
Morgan, G. J., & Wall, J. S. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.07.003 · Cited by 21
B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS
Schmidt, K., Sack, U., Graf, R., Winkler, W., Popp, O., Mertins, P., Sommermann, T. G., Kocks, C., & Rajewsky, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.602868 · Cited by 21
Delorme, S., & Baur‐Melnyk, A. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_7 · Cited by 20
Lambda Light Chain Deposition Disease in a Renal Allograft
Tanenbaum, N. D., Howell, D. N., Middleton, J. P., & Spurney, R. F. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.10.030 · Cited by 20
A Rational Diagnostic Approach to Peripheral Neuropathy
Smith, A. G., & Bromberg, M. B. (2003) · Journal of Clinical Neuromuscular Disease · doi:10.1097/00131402-200306000-00005 · Cited by 20
Morra, E., Cesana, C., Klersy, C., Varettoni, M., Cavanna, L., Canesi, B., Tresoldi, E., Barbarano, L., & Lazzarino, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50068 · Cited by 20
Herpes Zoster and Risk of Cancer in the Elderly U.S. Population
Mahale, P. S., Yanik, E. L., & Engels, E. A. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-1033 · Cited by 21
“Of interest, monoclonal gammopathy of undetermined significance and monoclonal B-cell lymphocytosis are asymptomatic premalignant conditions that canprecede by several years the development of multiple myeloma (39, 40), lymphoplasmacytic lymphoma (41), and CLL/SLL (42).”
Magnano, L., de Larrea, C. F., Elena, M., Cibeira, M. T., Tovar, N., Aróstegui, J. I., Pedrosa, F., Rosiñol, L., Filella, X., Yagüe, J., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.034 · Cited by 20
Kumar, S. K., Larson, D. R., Dispenzieri, A. A., Therneau, T. M., Murray, D. L., Bergsagel, P. L., Kyle, R. A., & Rajkumar, S. V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0210-z · Cited by 21
Self-citationClonal Hematopoiesis and Premalignant Diseases
Kaner, J. D., Desai, P. M., Mencia-Trinchant, N., Guzmán, M. L., Roboz, G. J., & Hassane, D. C. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035675 · Cited by 21
“Premalignant states are well-established in hematologic malignancies, including MBL as a precursor to chronic lymphocytic leukemia (CLL) and MGUS as a precursor to multiple myeloma (MM), progressing to full disease at a rate of 1% to 2% per year (Kyle et al. 2002; Rawstron et al. 2008).”
BackgroundPratt, G., Bowcock, S. J., Chantry, A., Cook, G., Jackson, G. H., Lai, M., Low, E., Mulholland, N. J. R., Owen, R. G., Rabin, N. K., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13620 · Cited by 19
“The pre-malignant stage most commonly detected incidentally is monoclonal gammopathy of uncertain significance (MGUS), which increases in incidence with age but has a low rate of progression to multiple myeloma at around 1% per year (Kyle et al, 2002).”
BackgroundBancu, I., Cañas, L., Juega, F. J., Pérez‐Mir, M., Malumbres, S., Bonet, J., & Lauzurica, R. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.08.023 · Cited by 19
“023 are considered risk factors for progression to a malignant condition [3,4].”
BackgroundEpigenetic silencing of EVL/miR-342 in multiple myeloma
Li, Z., Wong, K. Y., Chan, G., Chng, W. J., & Chim, C. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.005 · Cited by 19
Yamamoto, T., Kosaka, N., Hattori, Y., & Ochiya, T. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030055 · Cited by 21
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 21
Transient monoclonal gammopathy in a patient withBartonella quintana endocarditis
Sève, P., Turner, R., Stankovic, K., Pérard, L., & Broussolle, C. (2006) · American Journal of Hematology · doi:10.1002/ajh.20499 · Cited by 19
“In addition, a large number of nonmalignant conditions may be associated with a persistent or transient MG [1,2].”
BackgroundPrognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review
Cosemans, C., Oben, B., Arijs, I., Daniëls, A., Declercq, J., Vanhees, K., Froyen, G., Maes, B., Mebis, J., & Rummens, J. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.02.011 · Cited by 21
Fadia, M., Shroff, S., & Simpson, E. P. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0569-y · Cited by 19
Recent advances in the mangement of multiple myeloma.
Kumar, L., Vikram, P., & Kochupillai, V. (2006) · PubMed · Cited by 29
Kopper, P., Wiegrebe, S., Bischl, B., Bender, A., & Rügamer, D. (2022) · Lecture notes in computer science · doi:10.1007/978-3-031-05936-0_20 · Cited by 31
Epigenetic silencing of LPP/miR-28 in multiple myeloma
Li, Z., Wong, K. Y., Chan, G., & Chim, C. S. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204501 · Cited by 18
Circulating microRNAs and Their Role in Multiple Myeloma
Federico, C., Sacco, A., Belotti, A., Ribolla, R., Cancelli, V., Giacomini, A., Ronca, R., Chiarini, M., Imberti, L., Marini, M., et al. (2019) · Non-Coding RNA · doi:10.3390/ncrna5020037 · Cited by 19
Khouri, J., Faiman, B. M., Grabowski, D., Mahfouz, R. Z., Khan, S. N., Wei, W., Valent, J. N., Dean, R. M., Samaras, C. J., Jha, B. K., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.004 · Cited by 18
Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis
Murray, D. L., & Dasari, S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.03.003 · Cited by 20
Mehta, G. R., Suhail, F., Haddad, R. Y., Zalzaleh, G., & Lerma, E. V. (2014) · Disease-a-Month · doi:10.1016/j.disamonth.2014.08.002 · Cited by 18
hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies
Martín, P., Santón, A., García‐Cosío, M., & Bellas, C. (2006) · Modern Pathology · doi:10.1038/modpathol.3800590 · Cited by 18
“Currently, there are no reliable predictors for the progression of monoclonal gammopathy of undetermined significance to multiple myeloma or related disorders”
BackgroundShanafelt, T. D., Kay, N. E., Rabe, K. G., Call, T. G., Zent, C. S., Schwager, S. M., Leis, J. F., Jelinek, D. F., Slager, S. L., & Hanson, C. A. (2011) · Leukemia · doi:10.1038/leu.2011.211 · Cited by 18
Varettoni, M., Corso, A., Cocito, F., Mangiacavalli, S., Pascutto, C., Zappasodi, P., Pica, G.-M., & Lazzarino, M. (2010) · Medicine · doi:10.1097/md.0b013e3181e763be · Cited by 20
“2%.(11) In a large prospective study, using a competing risk model with death without transformation as competing event, the risk of transformation of MGUS into multiple myeloma or lymphoproliferative disorder was 3.”
BackgroundResultRossi, F. G., Petrucci, M. T., Guffanti, A., Marcheselli, L., Rossi, D., Callea, V., Federico, V., Muro, M. D., Baraldi, A., Villani, O., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3150 · Cited by 19
Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., & Rajkumar, S. V. (2007) · Translational medicine series · doi:10.3109/9781420045116.006 · Cited by 18
Self-citationPoisson models for person-years and expected rates
Atkinson, E. J., Crowson, C. S., Pedersen, R. A., & Therneau, T. M. (2008) · Cited by 18
Self-citationKwan, J. Y. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2006.12.002 · Cited by 19
Shaughnessy, J. D. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.9.1098 · Cited by 19
(2023) · doi:10.1182/bloodadvances.2023011608 · Cited by 17
Mitchell, J. S., Johnson, D. C., Litchfield, K., Broderick, P., Weinhold, N., Davies, F. E., Gregory, W. M., Jackson, G. H., Kaiser, M., Morgan, G. J., et al. (2015) · Scientific Reports · doi:10.1038/srep12473 · Cited by 17
Kapoor, P., Paludo, J., & Ansell, S. M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0391-7 · Cited by 17
Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation
Alfano, G., Fontana, F., Colaci, E., Messerotti, A., Bettelli, F., Potenza, L., Luppi, M., & Cappelli, G. (2017) · Transplantation · doi:10.1097/tp.0000000000001884 · Cited by 17
Júnior, A. D. D. C., Zanette, D. L., Pericole, F. V., Saad, S. T. O., & Carvalheira, J. B. C. (2021) · Advances in Hematology · doi:10.1155/2021/6615684 · Cited by 20
“(e incidence of progression into myeloma, lymphoma, or amyloidosis among patients with MGUS is about 1% per year [22].”
BackgroundWatanabe, T. (2021) · Cancers · doi:10.3390/cancers13122969 · Cited by 19
“In almost all patients with MM, a premalignant state called monoclonal gammopathy of undetermined significance (MGUS) precedes MM [2,3].”
BackgroundTargeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
Jiang, Q., Mao, H., He, G., & Mao, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215791 · Cited by 18
Monoclonal gammopathy of increasing significance: time to screen?
Chen, L., Drayson, M. T., Bunce, C. M., & Ramasamy, K. (2022) · Haematologica · doi:10.3324/haematol.2022.281802 · Cited by 17
Hoffbrand, A. V., & Hamblin, T. J. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.006 · Cited by 18
State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill, E., Dew, A., & Kazandjian, D. G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.03.001 · Cited by 17
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.